NYSE - Delayed Quote USD

Waters Corporation (WAT)

462.72 -17.35 (-3.61%)
At close: October 30 at 4:02:39 PM EDT
462.72 0.00 (0.00%)
After hours: October 30 at 4:08:35 PM EDT
Trade Waters on Coinbase
WAT Q3 2026 earnings call
November 3, 2026 at 8 AM EST
Chart Range Bar
Loading chart for WAT

What's happening with WAT?

53m ago
Powered by Yahoo Scout

Waters is approaching its November 3, 2026, third-quarter earnings report after announcing new software and diagnostic collaborations. The company is expanding artificial intelligence tools across laboratory workflows while integrating acquired businesses and managing China-related weakness.

Powered by Yahoo Scout
  • Previous Close 480.07
  • Open 479.04
  • Bid 461.61 x 4000
  • Ask 461.85 x 16000
  • Day's Range 458.85 - 479.60
  • 52 Week Range 282.77 - 482.28
  • Volume 1,342,305
  • Avg. Volume 813,446
  • Market Cap (intraday) 45.433B
  • Beta (5Y Monthly) 1.15
  • PE Ratio (TTM) 117.14
  • EPS (TTM) 3.95
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 465.86
  • Morningstar Rating
    Rating available with Stock Picks access

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

www.waters.com

16,000

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

WAT
21.82%
S&P 500 (^GSPC)
10.73%

1-Year Return

WAT
34.94%
S&P 500 (^GSPC)
11.11%

3-Year Return

WAT
95.49%
S&P 500 (^GSPC)
81.91%

5-Year Return

WAT
25.89%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.27B
Earnings -72M
Profit Margin -5.68%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
500M
1B
0.0%
10.0%
20.0%
 

Analyst Insights

View More

Top Analyst

Goldman Sachs
48/100
Latest Rating
Buy
 

Analyst Price Targets

349.00 Low
465.86 Average
462.72 Current
530.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 475 -> 515
 

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    45.43B

  • Enterprise Value

    50.35B

  • Trailing P/E

    117.14

  • Forward P/E

    27.22

  • PEG Ratio (current)

    22.63

  • Price/Sales (ttm)

    7.46

  • Price/Book (mrq)

    2.99

  • Enterprise Value/Revenue

    10.84

  • Enterprise Value/EBITDA

    53.27

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.59%

  • Return on Assets (ttm)

    3.56%

  • Return on Equity (ttm)

    1.92%

  • Revenue (ttm)

    4.64B

  • Net Income Avi to Common (ttm)

    166.63M

  • Diluted EPS (ttm)

    3.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    539M

  • Total Debt/Equity (mrq)

    36.04%

  • Levered Free Cash Flow (ttm)

    -142.07M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

462.72 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Raising target price to $515.00

    WATERS CORP has an Investment Rating of BUY; a target price of $515.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.

     
  • Raising target price to $487.00

    WATERS CORP has an Investment Rating of BUY; a target price of $487.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.

     
  • Lowering target price to $472.00

    WATERS CORP has an Investment Rating of BUY; a target price of $472.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.

     
  • Lowering target price to $480.00

    WATERS CORP has an Investment Rating of BUY; a target price of $480.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.

     

People Also Watch